BSG endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis

In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.

Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, the rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis.

Read More

BSG logo
Clinical Resources Categories
BSG Nurses Association
Inflammatory Bowel Disease
Practice recommendations for midwives caring for women and birthing people living with inflammatory bowel disease
clinical-resource/Practice-recommendations-for-midwives
The following practice recommendations were developed to standardise the midwifery care given to women and birthing people living with IBD during pregnancy.

BSG logo
Guidance
Colorectal
BSG/ACPGBI guidance on the management of colorectal polyps in patients with limited life expectancy
clinical-resource/Management-of-colorectal-polyps-in-patients
This BSG and ACPGBI guidance aims to help clinicians and patients consider these risks to aid decision-making for polypectomy versus a conservative approach.